Christoph Röllig, MD, MSc, Dresden University of Technology, Dresden, Germany, comments on FLT3-mutated acute myeloid leukemia (AML) data to be presented at the upcoming ASH 2021 Annual Meeting. Dr Röllig highlights a Phase III randomized study (NCT03182244) of gilteritinib versus salvage chemotherapy in patients with FLT3-mutated relapsed or refractory AML. The trial of over 200 patients demonstrated that gilteritinib significantly improved overall survival and event-free survival compared with salvage chemotherapy, validating previous data from the ADMIRAL trial. Dr Röllig also discusses the Phase 3 LACEWING trial (NCT02752035) of gilteritinib plus azacitidine compared to azacitidine alone in FLT3-mutated AML. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.